GlassScriptPhysician profile
Efrossini A Kolios
NPI 1124275797
$3,304.82
in general payments reported to CMS, 2019-2025
28 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $529 · 2023: $669 · 2024: $789 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.21 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $637.06 | 2021-2025 | Xtandi, Myrbetriq |
| Teleflex LLC | $368.51 | 2021-2025 | Urolift |
| Sumitomo Pharma America, INC. | $363.30 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $241.24 | 2021-2025 | |
| Axonics, INC. | $179.89 | 2023-2024 | Axonics, Bulkamid |
| Tolmar, INC. | $159.33 | 2023-2025 | Jatenzo, Eligard |
| Pfizer INC. | $134.17 | 2022-2025 | |
| Janssen Biotech, INC. | $126.69 | 2024-2025 | Erleada, Balversa, Akeega |
| Myriad Genetic Laboratories, INC. | $102.77 | 2024-2025 | Prolaris, Myrisk |
| Boston Scientific Corporation | $94.39 | 2023-2025 | Bulkamid, Rezum Generator, Ams 700 |
| Medtronic, INC. | $89.12 | 2024-2025 | Interstim |
| Olympus America INC. | $82.56 | 2023-2024 | Itind System, Uretero-Reno Fiberscope |
| Urovant Sciences INC | $80.42 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $79.39 | 2021-2022 | |
| Coloplast Corp | $78.17 | 2022-2025 | Speedicath |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $65.42 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $63.29 | 2023 | Givlaari |
| Accord Healthcare, INC. | $62.75 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $56.39 | 2021-2023 | Aveed, Xiaflex |
| Urogen Pharma, INC. | $46.11 | 2023-2024 | Jelmyto |
| Allergan, INC. | $43.58 | 2021 | |
| Blue Earth Diagnostics | $33.97 | 2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $26.10 | 2024 | |
| Laborie Medical Technologies Corp. | $19.86 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $19.82 | 2021 | |
| Merck Sharp & Dohme LLC | $18.82 | 2022 | |
| Calyxo, INC. | $17.70 | 2025 | Cvac Aspiration System |
| Therapeuticsmd, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrossini Kolios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.